Loading...
Loading...
LTRN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 43.8K |
| Gross Profit | -43.8K |
| Operating Expense | 5,190.3K |
| Operating I/L | -5,190.3K |
| Other Income/Expense | 443.9K |
| Interest Income | 117.8K |
| Pretax | -4,746.4K |
| Income Tax Expense | -117.8K |
| Net Income/Loss | -4,746.4K |
Lantern Pharma Inc. is a clinical stage biotechnology company leveraging artificial intelligence, machine learning, and genomic data to expedite drug development. Their lead drug candidate, LP-100, is in phase II clinical trials for metastatic, castration-resistant prostate cancer. They are also developing LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma, and LP-184, a preclinical alkylating agent targeting cancer cells with specific biomarkers or DNA repair pathway mutations. Additionally, the company operates an ADC program for cancer treatment. Their revenue is generated through the development and potential commercialization of these innovative drug candidates.
